Epstein-Barr virus (EBV) prevalence and the risk of reactivation in patients with inflammatory arthritis using anti-TNF agents and in those who are biologic naive

Open Rheumatology Journal

Volumn 3, Issue , 2009, Pages 30-34

  McKeown, Emily ^a   Pope, Janet E ^b   Leaf, Suzanne ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Anti TNF therapy; Epstein Barr virus; Lymphoma; Reactivation; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADULT; AGE; ARTHRITIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; GENDER; HUMAN; INFECTION RISK; LYMPHOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SIDE EFFECT; VIRUS REACTIVATION;

EID: 77950854936     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312900903010030     Document Type: Article

References (22)

1. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62: 1168-77.
2. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594-602.
3. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
4. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819-36.
5. Primer on the rheumatic diseases. Atlanta: Arthritis Foundation, 2001.
6. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42: 617-21.
7. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740-51.
8. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
9. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68(7): 1136-45.
10. Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283-350.
11. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1414-20.
12. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-9.
13. Losco A, Gianelli U, Cassani B, Baldini L, Conte D, Basilisco G. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 2004; 10: 425-9.
14. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261-81.
15. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-68.
16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. CASPAR Study Group. Arthritis Rheum 2006; 54(8): 2665-73.
17. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008; 10: 279-92.
18. Whelan P. Link between rheumatoid arthritis and cancer. Z Rheumatol 2006; 65: 497-2, 504.
19. Torre-Cisneros J, Del Castillo M, Caston JJ, Castro MC, Perez V, Collantes E. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1132-5.
20. Rohr JC, Wagner HJ, Lauten M, et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008; 12: 426-31.
21. Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004; 10: 85-90.
22. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of randomized controlled trials. Ann Rheum Dis 2009; 68(7): 1177-83.